Normunity

Normunity is a biotechnology company developing a new class of precision immuno-oncology drugs known as immune normalizers, aiming to unlock novel mechanisms of the body's normal immune response against cancer. Based on an ongoing interactive academic-biotech collaboration with the laboratory of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly discovered mechanisms of immune disruption in cancer, leveraging a proprietary discovery platform that elucidates the complex interactions between human cancers and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs aimed at mechanism-driven T-cell engagement in immunologically sensitive tumors and other mechanisms hindering normal cancer immunity functions.